Health & Fitness
Health and Fitness
Health and Fitness
Mon, June 7, 2010Sun, June 6, 2010Sat, June 5, 2010Fri, June 4, 2010Thu, June 3, 2010Wed, June 2, 2010Tue, June 1, 2010Mon, May 31, 2010Sat, May 29, 2010Fri, May 28, 2010Thu, May 27, 2010Wed, May 26, 2010Tue, May 25, 2010Mon, May 24, 2010Inhibitex to Present at Three Upcoming Conferences
Published in Health and Fitness on Friday, May 28th 2010 at 6:40 GMT by Market Wire
ATLANTA--([ BUSINESS WIRE ])--Inhibitex, Inc. (NASDAQ:INHX), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, announced that Russell H. Plumb, President and Chief Executive Officer, is scheduled to present an overview of the company and its pipeline of differentiated antiviral compounds at the following three conferences:
-- Noble Financial 6th Annual Equity Conference on Monday, June 7, 2010 at 10:00 am EDT. The conference is being held at The Seminole Hard Rock Hotel in Hollywood, Florida. The presentation will be simultaneously webcast and can be accessed by visiting the Investors section of the Inhibitex website at[ www.inhibitex.com ]. Shortly following the live webcast a replay will also be available on the Company website.
-- Jefferies Global Life Sciences Conference on Friday, June 11, 2010 at 10:30 am EDT. The conference is being held at The Grand Hyatt Hotel in New York City, New York.
-- ThinkEquity Mid-Year Checkup on Healthcare on Wednesday, June 16, 2010 at 8:30 am EDT. The conference is being held at The Princeton Club in New York City, New York.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to treat serious infectious diseases. The Companya™s pipeline includes FV-100, which is in Phase II clinical development, for the treatment of shingles, INX-189, a nucleotide polymerase inhibitor for the treatment of chronic hepatitis C infections currently in a Phase I study, and a staphylococcal vaccine based on its proprietary MSCRAMM protein platform that is partnered with Pfizer and currently in a Phase I study.
For additional information about the Company, please visit [ www.inhibitex.com ].
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.
